Jane F. Apperley

Nov 11, 2024 | nature.com | Joanna Drozd-Sokolowska |František Folber |Grzegorz W. Basak |Jane F. Apperley |Alessandro Rambaldi |Marek Trneny | +6 more

AbstractAutologous hematopoietic cell transplants (auto-HCTs) remain the standard of care for transplant-eligible MM patients. The general practice has been to undergo upfront apheresis following induction to collect sufficient number of CD34+ cells to facilitate two auto-HCTs. However, 5–30% of MM patients do not initially mobilise a sufficient number of hematopoietic stem cells and are classified as poor mobilizers (PM).

Sep 2, 2024 | nature.com | Elias Jabbour |Jane F. Apperley |Jorge Cortés |Michael Deininger |Elisabetta Abruzzese |Daniel DeAngelo | +2 more

Correction to: Leukemia https://doi.org/10.1038/s41375-024-02159-0, published online 29 January 2024Following publication of the article, the authors realized that several data points in Figure S3B and the accompanying manuscript text were incorrect. This oversight has been addressed and the corrected figure has been added. 1.

Feb 8, 2024 | nature.com | Jane F. Apperley

Dr Richard Szydlo, a senior biostatistician within the Centre for Haematology at Imperial College London (ICL), was a life-long resident of North-West London. His parents, Kazimierz and Daniela settled in the UK in the late 1940s, Kazimierz a distinguished and highly decorated veteran of the Carpathian Brigade, who had fought at Tobruk and throughout Italy, and Daniela as a refugee having survived deportation to Siberia followed by 5 years in Polish camps in India.

Jan 29, 2024 | nature.com | Elias Jabbour |Jane F. Apperley |Jorge Cortés |Michael Deininger |Elisabetta Abruzzese |Daniel DeAngelo | +2 more

AbstractPonatinib, the only approved all known-BCR::ABL1 inhibitor, is a third-generation tyrosine-kinase inhibitor (TKI) designed to inhibit BCR::ABL1 with or without any single resistance mutation, including T315I, and induced robust and durable responses at 45 mg/day in patients with CP-CML resistant to second-generation TKIs in the PACE trial.

Oct 24, 2023 | medscape.com | Michael J. Mauro |Jane F. Apperley

Authors and Disclosures Michael J. Mauro, MD Professor of Medicine, Weill Cornell Medicine; Director, CML Program, Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NYDisclosure: Michael J. Mauro, MD, has disclosed the following relevant financial relationships:Serve(d) as a consultant for: Novartis; Bristol Myers Squibb; Pfizer; Takeda; AbbVieReceived research grant from: Novartis; Bristol Myers Squibb; Takeda; Sun Pharma Jane F.